NBI-103

N/A

Report date: 2022/01/14 13:23:58
NME

Base Information

Drug NameNBI-103
Drug Alias NameNBI-103
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionCorticotropin-releasing factor receptor 2 antagonistsCorticotropin-releasing factor receptor 1 antagonists
TargetsCorticotropin-releasing factor receptor 1Corticotropin-releasing factor receptor 2
Therapy Area/IndicationsDepressive Disorder, MajorAnorexia NervosaAnxiety +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesNeurocrine Biosciences Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesNeurocrine Biosciences IncJohnson & Johnson
Active IndicationsN/A
Inactive IndicationsDepressive Disorder, MajorAnorexia NervosaAnxiety +[4] 

Other Information

ATC CodeN/A
Related LinksN/A